Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.46 |
| ▸ | CYP21A2 | P08686 | 7/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614881 | 1.00 | CYP17A1 (0.46) | CYP17A1CYP21A2CYP11B1MAPKAPK2CDC7 | |
| SCHEMBL27759523 | 0.91 | MAPKAPK2 (0.43) | CYP17A1CYP21A2CYP11B1MAPKAPK2CDC7 | |
| SCHEMBL3616381 | 0.89 | MAPKAPK2 (0.50) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3616384 | 0.89 | MAPKAPK2 (0.50) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3611782 | 0.87 | MAPKAPK2 (0.48) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3611785 | 0.87 | MAPKAPK2 (0.48) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3609560 | 0.86 | MAPKAPK2 (0.50) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3609561 | 0.86 | MAPKAPK2 (0.50) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3609550 | 0.85 | MAPKAPK2 (0.47) | MAPKAPK2CDC7MAPK1KITPLK4 | |
| SCHEMBL3609546 | 0.85 | MAPKAPK2 (0.47) | MAPKAPK2CDC7MAPK1KITPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | CYP17A1 149/4885CYP21A2 42/4885CYP11B1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.